Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: BNT116; Biological: Cemiplimab; Drug: Docetaxel; Drug: Carboplatin; Drug: Paclitaxel; Biological: BNT316; Biological: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor; Biological: anti-HER3 antibody conjugated to topoisomerase I inhibitor; Biological: Bispecific antibody for PD-L1 and VEGF-A; Biological: Osimertinib; Biological: ALK-inhibitor or RET-inhibitor
Sponsors: BioNTech SE
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
